Table 6

Cohort outcomes for new cases confirmed by culture


Total registered
Total remaining in cohorts** n, %
Excluded from cohorts* n, %
Cured n, %
Treatment completed n, %
Successful treatment n,% rows e+f
Failure n, %
Default n, %
Unsuccessful treatment n, % rows h+i
Died n, %
Lost and transferred out n, %

a
b
c
d
e
f
g
h
i
j
k
l

Civil
569
467 (82.1)
102(17.9)
106 (22.7)
263(56.3)
369(79.0%)
12(2.6)
36 (7.7)
48(10.3)
28 (6.0)
22 (4.7)
Smear+
207
161 (77.8)
46 (22.2)
106 (65.8)
0 (0.0)
106 (65.8%)
11 (6.8)
16 (9.9)
27 (16.8)
22 (13.7)
6 (3.7)
Smear-
362
306 (84.5)
56 (15.5)
0 (0.0)
263 (85.9)
263 (85.9%)
1 (0.3)
20 (6.5)
21 (6.9)
6 (2.0)
16 (5.2)
Culture+
---
266
---
95 (35.7)
103 (38.7)
198 (74.4%)
11 (4.1)
23 (8.6)
34 (12.8)
25 (9.4)
9 (3.4)
Culture-
---
201
---
11 (5.5)
160 (79.6)
171(85.1%)
1 (0.5)
13 (6.5)
14 (7.0)
3 (1.5)
13 (6.5)
Prison
351
319 (90.9)
32 (9.1)
5 (1.6)
218(68.3)
223(69.9%)
5 (1.6)
3 (0.9)
8 (2.5)
0 (0.0)
88(27.6)
Smear+
43
33 (76.7)
10 (23.3)
5 (15.2)
11 (33.3)
16 (48.5%)
2 (6.1)
0 (0.0)
2 (6.1)
0 (0.0)
15 (45.5)
Smear-
308
286 (92.9)
22 (7.1)
0 (0.0)
207 (72.4)
207 (72.4%)
3 (1.0)
3 (1.0)
6 (2.1)
0 (0.0)
73 (25.5)
Culture+
---
74
---
4 (5.4)
44 (59.5)
48 (64.9%)
3 (4.1)
0 (0.0)
3 (4.1)
0 (0.0)
23 (31.1)
Culture-
---
245
---
1 (0.4)
174 (71.0)
175 (71.4%)
2 (0.8)
3 (1.2)
5 (2.0)
0 (0.0)
65 (26.5)
Total
920
786 (85.4)
134(14.6)
111 (14.1)
481(61.2)
592(75.3%)
17(2.2)
40 (5.1)
57 (7.3)
28 (3.6)
110(14.0)
Smear+
250
194 (77.6)
56 (22.4)
111 (57.2)
11 (5.7)
122 (62.9%)
13(6.7)
16 (8.2)
29 (14.9)
22 (11.3)
21(10.8)
Smear-
670
592 (88.4)
78 (11.6)
0 (0.0)
470 (79.4)
470 (79.4%)
4 (0.7)
23 (3.9)
27 (4.6)
6 (1.0)
89(15.0)
Culture+
---
340
---
99 (29.1)
147 (43.2)
246 (72.4%)
14 (4.1)
23 (6.8)
37(10.9)
25 (7.4)
32 (9.4)
Culture-
---
446
---
12 (2.7)
334 (74.9)
346 (77.6%)
3 (0.7)
16 (3.6)
19 (4.3)
3 (0.7)
78 (17.5)

*a proportion of patients were excluded from cohort (transferred to a different regimen due to MDR TB, extensive radiological abnormalities, drug adverse reactions, severe accompanying pathology)

** N of patients remained in the cohort (column "total") is taken as a denominator

Balabanova et al. Respiratory Research 2006 7:44   doi:10.1186/1465-9921-7-44